Clinical Characteristics and Outcomes of Hypertensive Patients Infected with COVID-19: A Retrospective Study

Li Qin Chen¹*, Jiankun Chen¹,²*, Yuwan Wu¹, Jinyao Zhong¹, Fuzhen Zhou¹, Yuntao Liu¹,², Aiting Xu³, Jiqiang Li¹,², Huayang Cai¹

¹The Second Affiliated Hospital (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou University of Chinese Medicine, Guangzhou, 510006, Guangdong, People’s Republic of China; ²Guangzhou Key Laboratory of Traditional Chinese Medicine for Prevention and Treatment of Emerging Infectious Diseases, Guangzhou, 510006, Guangdong, People’s Republic of China; ³The People’s Hospital of Yangjiang, Yangjiang, 529500, Guangdong, People’s Republic of China

*These authors contributed equally to this work

Background: Hypertension has been reported as the most prevalent comorbidity in patients with coronavirus disease 2019 (COVID-19). This retrospective study aims to compare the clinical characteristics and outcomes in COVID-19 patients with or without hypertension.

Methods: A total of 944 hospitalized patients with laboratory-confirmed COVID-19 were included from January to March 2020. Information from the medical record, including clinical features, radiographic and laboratory results, complications, treatments, and clinical outcomes, were extracted for the analysis.

Results: A total of 311 (32.94%) patients had comorbidity with hypertension. In COVID-19 patients with hypertension, the coexistence of type 2 diabetes (56.06% vs 43.94%), coronary heart disease (65.71% vs 34.29%), poststroke syndrome (68.75% vs 31.25%) and chronic kidney diseases (77.78% vs 22.22%) was significantly higher, while the coexistence of hepatitis B infection (13.04% vs 86.96%) was significantly lower than in COVID-19 patients without hypertension. Computed tomography (CT) chest scans show that COVID-19 patients with hypertension have higher rates of pleural effusion than those without hypertension (56.60% vs 43.40%). In addition, the levels of blood glucose [5.80 (IQR, 5.05–7.50) vs 5.39 (IQR, 4.81–6.60)], erythrocyte sedimentation rate (ESR) [28 (IQR, 17.1–55.6) vs 21.8 (IQR, 11.5–44.1), P=0.008], C-reactive protein (CRP) [17.92 (IQR, 3.11–46.6) vs 3.15 (IQR, 3.11–23.4), P=0.013] and serum amyloid A (SAA) [99.28 (IQR, 8.85–300) vs 15.97 (IQR, 5.97–236.1), P=0.005] in COVID-19 patients with hypertension were significantly higher than in patients without hypertension.

Conclusion: It is common for patients with COVID-19 to have the coexistence of hypertension, type 2 diabetes, coronary heart disease and so on, which may exacerbate the severity of COVID-19. Therefore, optimal management of hypertension and other comorbidities is essential for better clinical outcomes.

Keywords: COVID-19, coronavirus disease, hypertension, clinical characteristics, comorbidities

Introduction

The coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a public health emergency worldwide. It typically presents with fever, cough, myalgia, and fatigue. As of July 22, 2021, there have been 191,773,590 confirmed cases and 4,127,963 deaths, with the numbers still rising across 217 countries/regions worldwide.¹ Therefore, COVID-19 has been considered a pandemic.²
Previous studies have suggested that the presence of comorbidities among COVID-19 may be associated with poor clinical outcomes.\(^3\) According to the latest reports, around 20–51% of patients with COVID-19 have at least one comorbidity,\(^4\) with hypertension (16.9%) and diabetes mellitus (8.2%) being the most prevalent comorbidities.\(^7\) A pooled analysis has indicated that hypertension may be related to a higher risk of severe or fatal COVID-19, especially in the elderly.\(^8\)

The angiotensin-converting enzyme 2 (ACE2) has been discovered to be the receptor that allows the entry of SARS-CoV-2 into human cells.\(^9,10\) ACE2 converts angiotensin II to Ang-(1-7), transforming the vasoconstrictor into a vasodilator peptide, which promotes the release of nitric oxide, decreases the outflow of sympathetic nerves, increases baroreflex sensitivity, and ultimately reduces hypertension.\(^11\) However, the relationship between COVID-19 and hypertension remains unclear.

The objective of this study was to elucidate the risk and severity of COVID-19 among patients with comorbid hypertension by investigating the clinical features, radiographic and laboratory results, complications, treatments, and clinical outcomes of COVID-19 patients with or without hypertension.

**Materials and Methods**

**Data Sources**

This was a retrospective study. We included 944 hospitalized COVID-19 patients from the Hubei Provincial Hospital of Integrated Traditional Chinese and Western Medicine from January 2020 to March 2020. All patients confirmed to have COVID-19 using a real-time reverse-transcriptase polymerase chain reaction (RT-PCR) assay of the sputum, throat swab, or lower respiratory tract secretion specimens were hospitalized for treatment. All patients were divided into hypertension group and non-hypertension group according to whether they had hypertension or not. Written informed consent was waived owing to the rapid emergence of this infectious disease and the urgent need to collect data.

The demographics, clinical symptoms or signs, radiological and laboratory results, comorbidities, and treatment results were extracted from the electronic medical record system. All medical data reviews and collections were processed by experienced clinicians. We established a computerized database for data storage and verification. Missing or incomplete information was acquired by sending requests for clarification to the coordinators, who subsequently contacted the attending clinicians. Major disagreements during the extraction process were resolved by consultation with the reviewers.

Finally, in accordance with the guidelines for prevention and treatment of hypertension in China (2018 Edition),\(^12\) we divided the patients into two groups: the COVID-19 with hypertension group and the non-hypertensive group (Hypertension was defined as: clinic systolic BP≥140 mmHg and/or diastolic BP≥90 mmHg without the use of anti-hypertensive medications at three visits on different days; with a BP<140/90 mmHg but having hypertensive history and currently are taking anti-hypertensive medication).

**Study Outcomes**

To assess the severity of COVID-19 among the patients with hypertension, the primary clinical outcomes included admission to an intensive care unit (ICU), discharge from the hospital, duration of hospitalization, and death.\(^13\)

**Laboratory Confirmation**

Laboratory confirmation of SARS-CoV-2 was performed in accordance with the protocol established by the World Health Organization using RT-PCR assays at Hubei Provincial Hospital of Integrated Traditional Chinese and Western Medicine. The laboratory confirmation processes were similar to the ones used in our previous study.\(^14\)

**Statistical Analysis**

Continuous variables are described as mean and standard deviation, and categorical variables are expressed as frequencies and percentages. Continuous variables were analyzed using an independent sample t-test when normally distributed; otherwise, the Mann–Whitney test was used. Categorical variables were compared using the chi-square test or Fisher’s exact test. All statistical analyses were performed using Statistical Package for the Social Sciences version 13.0 software (IBM; Chicago, Illinois, United States). Statistical significance was set at P <0.05.

**Results**

**Demographic and Clinical Characteristics**

This study included 944 patients with confirmed COVID-19 from the Hubei Provincial Hospital of Integrated Chinese and Western Medicine from January 2020 to March 2020. As shown in Tables 1, 311 (32.94%) patients had hypertension and 633 (67.06%) were non-hypertensive. The median age of the patients was 60
Table 1 Clinical Characteristics of the Study Patients with COVID-19

| Characteristic                          | No. (%)       | Hypertension | Non-Hypertension | P value |
|-----------------------------------------|---------------|--------------|------------------|---------|
|                                         | Total (100)   | 311 (32.94)  | 633 (67.06)      |         |
| Female sex - no. /total no. (%)         | 338 (35.81)   | 161 (32.26)  | 177 (34.83)      | 0.6377  |
| Age, Median (IQR) - year                | 60 (50–69)    | 67 (58–74)   | 53 (46–65)       | <0.0001 |
| Fever on admission (IQR) - °C           | 36.7 (36.5–37.0) | 36.7 (36.4–37.0) | 36.7 (36.5–37.0) | 0.8626  |
| Highest temperature during hospitalization (IQR) - °C | 37.2 (36.9–37.9) | 37.2 (36.9–37.9) | 37.2 (36.9–37.9) | 0.2767  |
| Systolic pressure on admission - mmHg   | 125 (110–135) | 130 (120–144) | 125 (110–135)   | <0.0001 |
| Diastolic pressure on admission - mmHg  | 80 (71–90)    | 82 (75–90)   | 78 (70–80)       | <0.0001 |
| Symptoms – no, %                        |               |              |                  |         |
| Chill                                   | 75 (7.94)     | 26 (34.67)   | 49 (63.33)       | 0.7409  |
| Cough                                   | 535 (56.67)   | 171 (31.96)  | 364 (68.04)      | 0.4627  |
| Sputum production                       | 202 (21.40)   | 66 (32.67)   | 136 (67.33)      | 0.9262  |
| Hemoptysis                              | 6 (0.64)      | 3 (50)       | 3 (50)           | 0.4018  |
| Sore throat                             | 29 (3.07)     | 9 (31.03)    | 20 (68.97)       | 0.8241  |
| Dry throat                              | 18 (2.54)     | 1 (6.25)     | 17 (93.75)       | 0.3985  |
| Itchy throat                            | 6 (0.82)      | 1 (6.25)     | 5 (93.75)        | 0.4774  |
| Nasal congestion                        | 9 (0.95)      | 2 (22.22)    | 7 (77.78)        | 0.4916  |
| Headache                                | 35 (3.71)     | 12 (34.29)   | 23 (65.71)       | 0.8634  |
| Shortness of breath                     | 272 (28.81)   | 99 (36.04)   | 173 (63.96)      | 0.1511  |
| Dyspnea                                 | 32 (3.43)     | 9 (28.13)    | 23 (71.87)       | 0.8234  |
| Conjunctival congestion                 | 4 (0.42)      | 1 (25.00)    | 3 (75.00)        | 0.7248  |
| Chest tightness                         | 172 (23.37)   | 54 (31.40)   | 118 (68.60)      | 0.6226  |
| Chest pain                              | 22 (2.99)     | 7 (31.82)    | 15 (68.18)       | 0.8411  |
| Palpitation                             | 32 (4.35)     | 4 (12.50)    | 28 (87.50)       | 0.0280  |
| Nausea or vomiting                      | 41 (4.34)     | 12 (29.27)   | 29 (70.73)       | 0.6086  |
| Diarrhea                                | 69 (7.31)     | 27 (39.13)   | 42 (60.87)       | 0.2562  |
| Myalgia or arthralgia                   | 125 (13.24)   | 47 (37.60)   | 78 (62.40)       | 0.2345  |
| Mental fatigue                          | 414 (56.25)   | 124 (29.95)  | 290 (70.05)      | 0.9676  |
| Loss of appetite                        | 451 (61.28)   | 141 (31.26)  | 310 (68.74)      | 0.3062  |
| Sleep disorder                          | 435 (59.10)   | 135 (30.93)  | 300 (69.07)      | 0.4154  |
| Fatigue                                 | 604 (63.98)   | 198 (32.78)  | 406 (67.22)      | 0.8868  |
| Coexisting disorder - no. (%)           |               |              |                  |         |
| Type 2 diabetes                         | 132 (13.98)   | 74 (56.06)   | 58 (43.94)       | <0.0001 |
| Coronary heart disease                  | 70 (7.42)     | 46 (65.71)   | 24 (34.29)       | <0.0001 |
| Poststroke syndrome                     | 32 (3.39)     | 22 (68.75)   | 10 (31.25)       | <0.0001 |
| Malignant tumor                         | 26 (2.75)     | 5 (19.23)    | 21 (80.77)       | 0.1304  |
| Chronic kidney disease                  | 9 (0.95)      | 7 (77.78)    | 2 (22.22)        | 0.007   |
| Chronic obstructive pulmonary disease   | 13 (1.38)     | 4 (30.77)    | 9 (69.23)        | 0.8665  |
| Asthma                                  | 6 (0.82)      | 3 (50)       | 3 (50)           | 0.28    |
| Heart failure                           | 6 (0.82)      | 3 (50)       | 3 (50)           | 0.28    |
| Arrhythmia                              | 18 (2.54)     | 9 (50)       | 9 (50)           | 0.06    |
| Bronchiectasis                          | 2 (0.27)      | 1 (50)       | 1 (50)           | 0.5088  |
| Hepatitis B infection*                  | 23 (2.44)     | 3 (13.04)    | 20 (86.96)       | 0.0431  |

Notes: *The presence of hepatitis B infection was defined as a positive result upon testing for the hepatitis B surface antigen, with or without elevated levels of alanine or aspartate aminotransferase. Arrhythmias refers to atrial fibrillation, frequent ventricular premature beats, and nodal tachycardia.
years (IQR, 50–69 years). A total of 35.81% of the participants were female. Fever (body temperature ≥ 37.5 °C) was present in 7.85% of the patients on admission, increasing to 33.16% during hospitalization. The most common symptoms were fatigue (63.98%), loss of appetite (61.28%), poor sleep quality (59.10%), cough (56.67%), and mental fatigue (56.25%). Among the overall population, 29.13% had at least one coexisting illness, including diabetes, poststroke syndrome, malignant tumor, and chronic kidney disease.

The mean age of the hypertensive patients was higher than that of the non-hypertensive patients (67 years [IQR, 58–74] vs 56 years [IQR, 46–65], P<0.001), consistent with previous reports. Furthermore, the systolic (130 mmHg [IQR, 120–144] vs 120 mmHg [IQR, 110–131], P<0.001) and diastolic blood pressures (82 mmHg [IQR, 75–90] vs 80 mmHg [IQR, 70–90], P<0.001) were significantly higher among patients with hypertension than among those without. Palpitation (12.50% vs 87.50%, P=0.028) was the only symptom that was statistically different between the two groups. It is possible that hypertensive patients were more likely to regularly take antihypertensive medication, making them less sensitive to palpitations.

Table 1 also shows significant differences in the comorbidities between COVID-19 patients with and without hypertension, including diabetes mellitus (56.06% vs 43.94%, P<0.001), coronary heart disease (65.71% vs 34.29%, P<0.001), poststroke syndrome (68.75% vs 31.25%, P<0.001), chronic kidney disease (77.78% vs 22.22%, P=0.007), and hepatitis B infection (13.04% vs 86.96%, P=0.043). However, malignant tumors, chronic obstructive pulmonary disease, asthma, heart failure, arrhythmia, and bronchiectasis were similar between the two groups.

**Radiologic and Laboratory Findings**

The radiologic indices (Table 2) showed that 767 (81.25%) of the patients had radiological abnormalities, including 572 cases (64.41%) with ground-glass opacity, 521 (58.67%) with local patchy shadowing, 521 (58.67%) with bilateral patchy shadowing, and 53 (5.97%) with pleural effusion, which are the typical features of an organizing pneumonia pattern of a lung injury. Compared with non-hypertensive patients, hypertensive patients had higher rates of pleural effusion (56.60% vs 43.40%, P<0.001), which may have resulted from bacterial superinfection or another cause among the hypertensive COVID-19 patients.

Table 3 shows the laboratory findings on admission. Blood glucose levels (5.80 mmol/L [IQR, 5.05–7.50] vs 5.39 mmol/L [IQR, 4.8–6.60]) in COVID-19 patients with hypertension were significantly higher than those in patients without hypertension (P=0.007). The hypertensive patients did not have disorders in glucose metabolism because the HbA1c levels were within the normal range. On admission, the white cell count (5.97 g/L [IQR, 4.74–7.67] vs 5.48 g/L [IQR, 4.30–6.82]) in COVID-19 patients with hypertension were significantly higher than that in those without hypertension (P<0.001), while the hemoglobin count was higher in COVID-19 patients without hypertension (125.6 g/L [IQR, 114.5–136] vs 127 g/L [IQR, 116–138], P=0.0316). However, since the parameters were within the normal range, no clinically significant effects were noted.

The levels of the inflammatory markers, including the erythrocyte sedimentation rate (28 mm/h [IQR, 17.1–55.6] vs 21.8 mm/h [IQR, 11.5–44.1], P=0.008) and C-reactive protein level (17.92 mg/L [IQR, 3.11–46.6] vs 3.15 mg/L [IQR, 3.11–23.4], P=0.013), were elevated, but there were no significant differences between the groups. This suggests that COVID-19 patients with hypertension were more likely to develop more severe infections. Meanwhile, the pro-inflammatory cytokines, such as procalcitonin, tumor necrosis factor, and interleukins, did not change in either COVID-19 group. The levels of immunity parameters showed that the serum concentrations of IgE (50.15 g/L [IQR, 18.5–142.5] vs 38.7 g/L [IQR, 18.3–95.8]) were

### Table 2 Radiographic Examination Results

| Variable- No./Total No. (%) | Total | Hypertension | Non-Hypertension | P value |
|-----------------------------|-------|--------------|------------------|---------|
| Abnormalities on chest CT   |       |              |                  |         |
| Ground-glass opacity        | 944 (100) | 311 (32.94) | 633 (67.06) |         |
| Local patchy shadowing      | 572 (64.41) | 195 (34.09) | 377 (65.91) | 0.3026 |
| Bilateral patchy shadowing  | 76 (8.56) | 25 (32.89) | 51 (67.11) | 0.9982 |
| Pleural effusion            | 521 (58.67) | 183 (35.12) | 338 (64.88) | 0.0902 |
|                            | 53 (5.97) | 30 (56.60) | 23 (43.40) | 0.0002 |
## Table 3 Laboratory Findings

| Variable- No./Total No. (%) | No. (%) | P value |
|-----------------------------|---------|---------|
|                             | Total   | Hypertension | Non-Hypertension |
| Blood glucose and lipids    | 944 (100) | 311 (32.94) | 633 (67.06) |
| Random blood glucose - mmol/L | 5.53 (4.88–6.94) | 5.80 (5.05–7.50) | 5.39 (4.81–6.60) | 0.0066 |
| HbA1c - %                   | 2 (2–5.2) | 2 (2–3) | 2 (2–5.3) | 0.4810 |
| TC - mmol/L                 | 4.22 (3.64–4.81) | 4.19 (3.64–4.73) | 4.23 (3.66–4.67) | 0.7850 |
| TG - mmol/L                 | 1.30 (0.94–1.72) | 1.33 (0.95–1.81) | 1.27 (0.93–1.70) | 0.3223 |
| LDL-C - mmol/L              | 1.79 (1.46–2.17) | 1.77 (1.50–2.18) | 1.80 (1.42–2.17) | 0.8271 |
| HDL-C - mmol/L              | 1.10 (0.93–1.30) | 1.12 (0.89–0.23) | 1.10 (0.95–1.30) | 0.3518 |
| Hematologic                 |         |         |         |
| White cell count - g/L      | 5.61 (4.47–7.09) | 5.97 (4.74–7.67) | 5.48 (4.3–6.82) | 0.0008 |
| Lymphocyte count - g/L      | 1.32 (0.88–1.77) | 1.28 (0.83–1.72) | 1.36 (0.91–1.82) | 0.2339 |
| Platelet count - g/L        | 220 (169–277) | 221 (164–288) | 218.5 (171–272) | 0.2809 |
| Hemoglobin - g/L            | 127 (116–137) | 125.6 (114.5–136) | 127 (116–138) | 0.0316 |
| Inflammatory                |         |         |         |
| ESR - mm/h                  | 25 (13.5–48.1) | 28 (17.1–55.6) | 21.8 (11.5–44.1) | 0.0083 |
| TNF - fmol/mL                | 9.3 (6.8–12.7) | 9.9 (7.03–14.2) | 9.3 (6.49–12.1) | 0.7094 |
| IL-1β - pg/mL                | 5 (5–5.8) | 5 (5–5.8) | 5 (5–5.72) | 0.3926 |
| IL-10 - pg/mL                | 5 (5–7.2) | 5 (5–7.8) | 5 (5–6.6) | 0.1855 |
| IL-6 - pg/mL                 | 5.3 (2.6–16.1) | 6.02 (3.02–18.2) | 4.95 (2.49–14.8) | 0.2482 |
| PCT - ng/mL                  | 0.03 (0.02–0.07) | 0.04 (0.02–0.08) | 0.03 (0.02–0.06) | 0.5126 |
| CRP - mg/L                   | 5.85 (3.11–3.71) | 17.92 (3.11–46.6) | 3.15 (3.11–23.4) | 0.0131 |
| Immune                       |         |         |         |
| IgA - g/L                    | 2.19 (1.84–2.7) | 2.22 (1.85–2.79) | 2.18 (1.84–2.61) | 0.1964 |
| IgM - g/L                    | 0.99 (0.79–1.28) | 0.89 (0.68–1.15) | 1.03 (0.85–1.34) | <0.0001 |
| IgG - g/L                    | 1.17 (1.03–13.3) | 1.19 (1.08–13.2) | 1.17 (1.02–13.4) | 0.4999 |
| IgE - g/L                    | 40.6 (18.3–115.0) | 50.15 (18.50–142.5) | 38.7 (18.3–95.8) | 0.0363 |
| C3 - g/L                     | 1.18 (1.03–1.33) | 1.22 (1.11–1.37) | 1.16 (0.98–1.29) | 0.5755 |
| C4 - g/L                     | 0.26 (0.21–0.33) | 0.27 (0.24–0.34) | 0.25 (0.20–0.32) | 0.0196 |
| Total T lymphocytes - %      | 68.1 (59.79–74.2) | 66.43 (57.09–73.05) | 69.14 (61.04–74.65) | 0.0633 |
| Total T lymphocytes count    | 618 (372–821) | 546 (282–787) | 662.5 (421–838) | 0.0364 |
| Cytotoxic T lymphocytes - %  | 23.30 (17.2–29.8) | 20.66 (15.86–28.16) | 24.32 (18.36–30.33) | 0.0580 |
| Cytotoxic T lymphocytes count| 205 (118–299) | 170 (100–266) | 211.5 (134–313) | 0.1275 |
| Helper T cells - %           | 40.76 (33.2–48.18) | 41.54 (32.94–48.82) | 40.04 (34.03–47.91) | 0.6426 |
| Helper T cells count         | 364 (225–512) | 345.5 (167–508) | 372 (241–514) | 0.2946 |
| B lymphocytes - %            | 13.68 (9.88–19.22) | 13.50 (9.40–19.32) | 13.7 (10.08–19.04) | 0.8565 |
| B lymphocytes count          | 112 (77–172.5) | 103 (64.5–151.5) | 116 (83.5–183.5) | 0.0445 |
| K cells - %                  | 13.85 (8.88–20.34) | 15.66 (9.94–22.75) | 13.26 (8.50–19.44) | 0.0120 |
| K cells count                | 112 (65.5–181.5) | 116 (65.5–187.5) | 110.5 (65.5–178) | 0.5853 |
| Lymphocytes count            | 908 (609–1167) | 851 (530–1122) | 951 (678–1199) | 0.1020 |
| Helper/Cytotoxic T lymphocytes ratio | 1.78 (1.26–2.54) | 2.10 (1.38–2.66) | 1.64 (1.19–2.32) | 0.2465 |
| Coagulation                  |         |         |         |
| Fibrinogen - g/L             | 2.91 (2.32–3.88) | 3.03 (2.44–3.97) | 2.84 (2.25–3.83) | 0.0116 |
| PT - s                       | 12.1 (11.3–13.1) | 12.1 (11.2–13.1) | 12.1 (11.3–13.1) | 0.4645 |
| INR                          | 1.01 (0.94–1.10) | 1.01 (0.94–1.09) | 1.01 (0.95–1.10) | 0.3082 |
| PAP                          | 99 (94–104) | 99 (94–104) | 99 (94–103.8) | 0.1569 |
| APTT - s                     | 30.00 (27.7–32.2) | 29.45 (27.3–32.2) | 30.1 (27.9–32.2) | 0.5937 |
| TT - s                       | 15.75 (14.85–17.01) | 15.8 (14.9–17.1) | 15.7 (14.8–17.0) | 0.3625 |
| D-dimer - mg/L               | 0.48 (0.32–0.97) | 0.59 (0.38–1.30) | 0.43 (0.29–0.89) | 0.3873 |

(Continued)
Table 3 (Continued).

| Variable- No./Total No. (%)         | No. (%)          | Total   | Hypertension | Non-Hypertension | P value |
|------------------------------------|------------------|---------|--------------|------------------|---------|
|                                    |                  |         |              |                  |         |
| **Biochemical**                    |                  |         |              |                  |         |
| BNP - pg/mL                        | 26 (10–64)       | 37.5 (13–91) | 23 (10–50.5) | 0.0042           |
| ALT - IU/L                         | 20 (11–35)       | 20 (12–35) | 20 (11–35.5) | 0.4357           |
| AST - IU/L                         | 22 (16–32)       | 23 (16–35) | 21 (16–31)   | 0.3370           |
| TP - g/L                           | 63.6 (59.5–67.5) | 63.75 (60.1–67.9) | 63.45 (59.3–67.1) | 0.3625 |
| ALB - g/L                          | 37.85 (34.3–41.2) | 37.4 (34.0–40.3) | 38.1 (34.5–41.4) | 0.1262 |
| PA - g/L                           | 153.7 (106.2–211.5) | 154.7 (103.1–219.2) | 153.6 (107.7–206.5) | 0.5847 |
| GLB - g/L                          | 25.8 (22.4–29.01) | 26.1 (23.3–29.5) | 25.5 (22.01–28.8) | 0.6356 |
| Cys-C - mg/L                       | 0.79 (0.66–0.98) | 0.90 (0.74–1.16) | 0.75 (0.64–0.89) | <0.0001 |
| TBIL - μmol/L                      | 11 (8.2–14.6)    | 11.5 (8.4–15.8) | 10.9 (8.2–14.1) | 0.0578 |
| CRE - μmol/L                       | 66.3 (56.8–81.3) | 72.75 (60.4–86.4) | 64 (55.2–78.2) | <0.0001 |
| BUN- mmol/L                        | 4.76 (3.76–6.01) | 5.16 (4.08–6.65) | 4.53 (3.67–5.72) | 0.0741 |
| UA- mmol/L                         | 269.7 (219.7–340.1) | 290.3 (237.4–365.8) | 260.5 (213.5–321.7) | <0.0001 |
| Creatinine - μmol/L               | 63 (39–104.5)    | 64 (42–105) | 62 (38–103) | 0.9357 |
| LDH - U/L                          | 210 (170.5–278.0) | 219 (180–298) | 204 (168–266) | 0.3137 |
| SAA- mg/L                          | 22.18 (6.02–254.04) | 99.28 (8.85–300) | 15.97 (5.97–236.1) | 0.0050 |

**Blood Gas Analysis**

| Variable- No./Total No. (%)         | No. (%)          | Total   | Hypertension | Non-Hypertension | P value |
|------------------------------------|------------------|---------|--------------|------------------|---------|
|                                    |                  |         |              |                  |         |
| PH                                 | 7.45 (7.42–7.48) | 7.45 (7.42–7.48) | 7.45 (7.42–7.48) | 0.5964 |
| PCO2 - mmHg                        | 36 (33–41)       | 35 (33–41) | 37 (32.5–41) | 0.6320 |
| PCO2 - mmHg                        | 94 (69–123)      | 85 (70–113) | 98.5 (68.5–134) | 0.0264 |

**Minerals**

| Variable- No./Total No. (%)         | No. (%)          | Total   | Hypertension | Non-Hypertension | P value |
|------------------------------------|------------------|---------|--------------|------------------|---------|
|                                    |                  |         |              |                  |         |
| Sodium - mmol/L                    | 139.7 (137.4–141.3) | 139.5 (137–141.3) | 139.8 (137.5–141.3) | 0.2377 |
| Potassium - mmol/L                 | 3.82 (3.51–4.21) | 3.77 (3.42–4.21) | 3.85 (3.55–4.20) | 0.1796 |
| Chloride - mmol/L                  | 106 (103.6–107.7) | 105.7 (102.8–107.4) | 106.0 (103.7–107.8) | 0.0488 |

**Abbreviations:** Hba1c, glycosylated hemoglobin A1; TC, total cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; PCT, procalcitonin; TNF, tumor necrosis factor; IL, interleukin; BUN, blood urea nitrogen; PT, prothrombin time; INR, international normalized ratio; APTT, activated partial thromboplastin time; PAP, prothrombin activation percentage; TT, thrombin time; LDH, lactic dehydrogenase; Ig, immunoglobulin; C3, complement 3; C4, complement 4; AST, aspartate aminotransferase; ALT, alanine aminotransferase; SAA, serum amyloid A; PH, pondus hydrogenii.

Increased (P=0.036), whereas the serum levels of complement 4 (0.27 g/L [IQR, 0.24–0.34] vs 0.25 g/L [IQR, 0.20–0.32]) were decreased (P=0.020) in the hypertensive COVID-19 patients when compared with the non-hypertensive COVID-19 patients. The level of complement 4 was decreased in both groups, indicating viral infection. The IgM level, total T lymphocyte count, B lymphocyte count, and percentage of K cells showed positive changes, but no clinical manifestations were observed.

Compared to the COVID-19 group without hypertension, the COVID-19 group with hypertension had a higher level of fibrinogen, though its level was within the normal range in both groups. The levels of D-dimer, activated partial thromboplastin time, thrombin time, etc. were within the laboratory ranges, suggesting a more or less normal blood coagulation function. Serum amyloid A levels were higher in the hypertensive group than in the non-hypertensive group (99.28 mg/L [IQR, 8.85–300] vs 15.97 mg/L [IQR, 5.97–236.1], P=0.005), suggesting acute infection. The level of the brain natriuretic peptide showed a positive change, but it was clinically irrelevant. Although cystatin C, creatinine, and uric acid levels of both the hypertensive and non-hypertensive groups were within normal range, the hypertensive patients had higher cystatin C (0.90 mg/L [IQR, 0.74–1.16] vs 0.75 mg/L [IQR, 0.64–0.89], P < 0.001), creatinine, and uric acid levels than the non-hypertensive patients, possibly indicating renal function injury. No abnormalities were noted in the levels of alanine aminotransferase, aspartate aminotransferase, and blood urea nitrogen. Compared to the non-hypertensive patients, the hypertensive patients had much lower PO2 (85 mmHg [IQR, 70–113] vs 98.5 mmHg [IQR, 68.5–134], P=0.026). This may be related to the ACE2 levels,
as it has been previously reported that hypoxia could decrease ACE2 expression in the lung tissues of rats.  

**Clinical Outcomes**

As shown in Table 4, 86 patients were admitted to the ICU and 904 patients were discharged from the hospital. There were no significant differences in the incidence of ICU admission and hospital discharge between the two groups. No deaths were observed during the entire study. The median duration of hospitalization was 14 days (median, 9–20 days). Patients with hypertension had significantly longer hospital stays (14 [IQR, 9–21] vs 13 [IQR, 8–19], P=0.022) than those without hypertension.

**Treatment and Complications**

All COVID-19 patients received symptomatic treatment. The majority of the patients (77.67%) received antiviral therapy, while 61.5% received intravenous antibiotic therapy. Furthermore, 31.31% received systemic glucocorticoids, and 1.44% received antifungal medication. The majority (89.62%) received oxygen therapy, while only a few required invasive (1.52%) and noninvasive mechanical ventilation (7.16%). In addition, 83.93% received traditional Chinese medicine treatment, 69.92% received Chinese patent medicine treatment, and 16.68% received acupuncture or ear acupoint therapy. There were no significant differences in the above treatment measures between the COVID-19 patients with and without hypertension.

**Table 4 Complications, Treatments, and Clinical Outcomes**

| Variable                                    | Total       | Hypertension | Non-Hypertension | P value |
|---------------------------------------------|-------------|--------------|------------------|---------|
| Complications                               |             |              |                  |         |
| Septic shock - no. (%)                      | 10 (1.07)   | 2 (20.00)    | 8 (80.00)        | 0.3922  |
| Heart failure - no. (%)                     | 14 (1.50)   | 8 (57.14)    | 6 (42.86)        | 0.0799  |
| Acute respiratory distress syndrome - no. (%)| 48 (5.15)   | 15 (31.25)   | 33 (68.75)       | 0.8356  |
| Acute kidney injury - no. (%)               | 10 (1.07)   | 5 (50)       | 5 (50)           | 0.2385  |
| Disseminated intravascular coagulation - no. (%)| 2 (0.21)   | 1 (50)       | 1 (50)           | 0.5467  |
| Rhabdomyolysis - no. (%)                   | 1 (0.11)    | 0 (0.00)     | 1 (100.00)       | 1.0000  |
| Treatments                                  |             |              |                  |         |
| Anti-hypertensive medication - no. (%)      | 264 (35.87) | 164 (62.12)  | 100 (37.88)      | <0.0001 |
| Antidiabetic medication - no. (%)           | 50 (6.79)   | 22 (44.00)   | 28 (56.00)       | 0.0362  |
| Lipid-lowering medication - no. (%)         | 65 (8.83)   | 40 (61.54)   | 25 (38.46)       | <0.0001 |
| Intravenous antibiotics - no. (%)           | 567 (61.50) | 192 (33.86)  | 375 (66.14)      | 0.2780  |
| Antifungal medication - no. (%)             | 13 (1.44)   | 6 (46.15)    | 7 (53.85)        | 0.2747  |
| Antiviral medication - no. (%)              | 714 (76.77) | 243 (34.03)  | 471 (65.97)      | 0.0561  |
| Systemic glucocorticoids - no. (%)          | 284 (31.31) | 98 (34.51)   | 186 (65.49)      | 0.2912  |
| Oxygen therapy- no. (%)                     | 798 (85.62) | 267 (33.46)  | 531 (66.54)      | 0.1816  |
| Invasive mechanical ventilation - no. (%)   | 14 (1.52)   | 6 (42.86)    | 8 (57.14)        | 0.3940  |
| Noninvasive mechanical ventilation - no. (%)| 66 (7.16)   | 28 (42.42)   | 38 (57.58)       | 0.0754  |
| Intravenous immunoglobulin- no. (%)         | 227 (24.57) | 78 (34.36)   | 149 (65.64)      | 0.4336  |
| Traditional Chinese Medicine - no. (%)      | 781 (83.93) | 245 (31.37)  | 536 (68.63)      | 0.1052  |
| Chinese Patent Medicine - no. (%)           | 651 (69.92) | 214 (32.87)  | 437 (67.13)      | 0.7029  |
| Acupuncture or ear acupoint - no. (%)       | 154 (16.68) | 59 (38.31)   | 95 (61.69)       | 0.0856  |
| Clinical outcomes at data cutoff            |             |              |                  |         |
| Admission to intensive care unit - no. (%)  | 86 (9.12)   | 32 (37.21)   | 54 (62.79)       | 0.3815  |
| Discharge from hospital                     | 904 (95.76) | 294 (32.52)  | 610 (67.48)      | 0.1889  |
| Median length of hospital stay (IQR) - days  | 13 (9–20)   | 14 (9–21)    | 13 (8–19)        | 0.0216  |

**Table 4** Complications, Treatments, and Clinical Outcomes
During hospital admission, patients were diagnosed with acute respiratory distress syndrome (5.15%), acute heart failure (1.50%), septic shock (1.07%), acute kidney injury (1.07%), disseminated intravascular coagulation (DIC) (0.21%), and rhabdomyolysis (0.11%). However, all the above-mentioned diagnoses showed similar incidences in the two groups.

Discussion

Compared to the diseases associated with previous coronavirus epidemics, such as the Severe Acute Respiratory Syndrome and the Middle East Respiratory Syndrome, COVID-19 is more severe and has a faster spread.\(^{18}\) SARS-CoV-2 enters cells through the ACE2 receptor, considered the functional receptor for this coronavirus.\(^{19}\) Additionally, ACE2 is regarded as a potent modulator of blood pressure, and its deficiency leads to hypertension.\(^{20}\) Due to the interaction between SARS-CoV-2 and ACE2, it is believed that hypertension may be related to the pathogenesis of COVID-19 by working directly as a previous clinical predictor of disease severity or by leading to late deterioration in the disease process.\(^{8}\)

Hypertension, diabetes, chronic obstructive pulmonary disease, cardiovascular disease, and cerebrovascular disease are risk factors for COVID-19.\(^{21–25}\) In this retrospective cohort study, we focused on hypertension as it was the most prevalent comorbidity among patients with COVID-19. The median age of the COVID-19 patients was 60 years, and the prevalence rate of hypertension was 32.94%. We found no difference in the patients’ sex distribution, but the patients with hypertension were older and had higher blood pressures, consistent with a previous study.\(^{26}\) This may be due to the higher median age of the patients we included. Normally, the frequency of palpitation is higher in patients with hypertension. However, in our study, the incidence of palpitations was lower in the hypertensive group, which could have resulted from the small number of patients with palpitation or the presence of drug interventions in hypertensive patients. Our study indicated that hypertensive COVID-19 patients had more comorbidities, such as diabetes mellitus, coronary heart disease, pleural effusion, and chronic kidney disease.

Chest CT images proved that patients with hypertension had higher rates of pleural effusion than those without hypertension, indicating that the former had more severe lung pathologies.\(^{27}\) Furthermore, the levels of the inflammatory markers, such as the erythrocyte sedimentation rate, serum amyloid A, and C-reactive protein, were elevated in the COVID-19 patients, pointing to an increased likelihood of developing cytokine storm in these patients. Furthermore, the levels of these markers were significantly higher in patients with hypertension than in those without hypertension. Integrating these results with the chest CT results above, we can surmise that COVID-19 patients with hypertension were more likely to develop a more severe infection. Hence, patients in the hypertensive group had longer hospital stays than those in the non-hypertensive group. Moreover, there was no significant difference in clinical treatment between the two groups, except for the use of antihypertensive and lipid-lowering drugs.

Study Limitations

Our study had the following limitations. First, this study was retrospective and non-randomized. Thus, the clinical outcomes were not as accurate as those in prospective studies. Second, the severity of COVID-19 was not graded. As such, the proportion of patients with each grade could not be determined. Third, due to the outbreak isolation management and lack of equipment, the blood pressure was not measured daily. Fourth, systemic glucocorticoids have been widely used to treat COVID-19 patients, which may influence blood pressure. Therefore, multicenter and prospective studies are necessary to further explore the risk factors and severe events in COVID-19 patients with hypertension.

Conclusion

In conclusion, hypertension worsens the morbidity of COVID-19 patients. This study provided at least two essential lessons for the clinical management of COVID-19. First, controlling blood pressure in COVID-19 patients with hypertension is necessary. Second, increased clinical vigilance is warranted for COVID-19 patients with hypertension, given its chronicity and associated morbidity.

Ethics Statement

The study was performed in accordance with the Declaration of Helsinki and carried out in accordance with the recommendations of Chinese National Guidelines and Ethics Branch of the Biomedical Ethics Committee of Guangzhou University of Chinese Medicine (ZE2020-049-01).
Acknowledgments
The authors are grateful to the doctors and nurses of Hubei Provincial Integrated Traditional Chinese and Western Medicine Hospital for their assistance.

Author Contributions
All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; agreed to submit to the current journal; gave final approval of the version to be published; and agree to be accountable for all aspects of the work.

Funding
This work was supported by the National Key Research and Development Plan of China (2020YFA0708001, 2020YFC0845300, 2020YFC0841600), the Guangdong Province Science and Technology Planning Project (2019A070717007), the Guangdong Provincial Department of Education Project (2020KZDZX1054), the Fund of Guangzhou University of Chinese Medicine (2021KX06, 2021KX49, 2021YJZX012), the Guangdong Provincial Bureau of Chinese Medicine (20212094 and 20191377), and the Guangdong Provincial Hospital of Chinese Medicine Fund (YN2019ML11 and YN2019QJ13).

Disclosure
The authors declare no conflicts of interest in relation to this work.

References
1. WHO. WHO Coronavirus disease (COVID-19) dashboard; 2021. Available from: https://covid19.who.int/. Accessed August 13, 2021.
2. Tian J, Yuan X, Xiao J, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020;21(7):893–903.
3. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069. doi:10.1001/jama.2020.1585
4. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395 (10223):497–506. doi:10.1016/S0140-6736(20)30183-5
5. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395 (10223):507–513. doi:10.1016/S0140-6736(20)30211-7
6. Liu K, Fang Y, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl). 2020;133(9):1025–1031. doi:10.1097/CM9.000000000000744
7. Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547. doi:10.1183/13993003.00547-2020
8. Lippi G, Wong J, Henry BM. Hypertension in patients with coronavirus disease 2019 (COVID-19): a pooled analysis. Pol Arch Intern Med. 2020;130(4):304–309. doi:10.20452/pamw.15272
9. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579 (7798):270–273. doi:10.1038/s41586-020-02012-7
10. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8. doi:10.1016/j.cell.2020.02.052
11. Xu J, Srimulam S, Xia H, et al. Clinical relevance and role of neuronal AT1 receptors in ADAM17-mediated ACE2 shedding in neurogenic hypertension. Circ Res. 2017;121(1):43–55. doi:10.1161/ CIRCRESAHA.116.310509
12. Joint Committee for Guideline Revision. 2018 Chinese guidelines for prevention and treatment of hypertension—a report of the revision Committee of Chinese Guidelines for prevention and treatment of hypertension. J Geriatr Cardiol. 2019;16(3):182–241. doi:10.11909/j. issn.1671-5411.2019.03.014.
13. Jin X, Pang B, Zhang J, et al. Core outcome set for clinical trials on Coronavirus disease 2019 (COS-COVID), Engineering (Beijing). 2020;6(10):1147–1152. doi:10.1016/j.eng.2020.03.002
14. Chen Y, Chen J, Gong X, et al. Clinical characteristics and outcomes of type 2 diabetes patients infected with COVID-19: a retrospective study. Engineering (Beijing). 2020;6(10):1170–1177. doi:10.1016/j. eng.2020.05.017
15. Grasselli G, Zaninello A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323 (16):1574–1581. doi:10.1001/jama.2020.5394
16. Kanne JP, Little BP, Chung JH, Elicker BM, Ketai LH. Essentials for radiologists on COVID-19: an update-radiology scientific expert panel. Radiology. 2020;296(2):E113–E114. doi:10.1148/radiol. 2020200527
17. Hu JH, Zhang RF, Dong LL, Chen EG, Ying KJ. Overexpression of ACE2 prevents hypoxia-induced pulmonary hypertension in rats by inhibiting proliferation and immigration of PASMCs. Theranostics. 2020;24(7):3968–3980. doi:10.26555/ eurrev.202004.20867
18. Datta PK, Liu F, Fischer T, Rappaport J, Qin X. SARS-CoV-2 pandemic and research gaps: understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. Theranostics. 2020;10(16):7448–7464. doi:10.7150/thno.48076
19. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(2):281–292.e6. doi:10.1016/j. cell.2020.02.058
20. Patel VB, Zhong JC, Grant MB, Oudit GY. Role of the ACE2/angiotensin 1-7 axis of the renin-angiotensin system in heart failure. Circ Res. 2016;118(8):1313–1326. doi:10.1161/CIRCRESAHA.1 16.307708
21. Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY). 2020;12(7):6049–6057. doi:10.18632/aging.103000
22. Li M, Dong Y, Wang H, et al. Cardiovascular disease potentially contributes to the progression and poor prognosis of COVID-19. Nutr Metab Cardiovasc Dis. 2020;30(7):1061–1067. doi:10.1016/j. numecd.2020.04.013
23. Katz JM, Libman RB, Wang JJ, et al. Cerebrovascular complications of COVID-19. Stroke. 2020;51(9):e227–e231. doi:10.1161/ STROKEAHA.120.031265
24. Amar J, Touront N, Ciron AM, Pendaries C. Interactions between hypertension and inflammatory tone and the effect on blood pressure and outcomes in patients with COVID-19. *J Clin Hypertens (Greenwich)*. 2021;23(2):238–244. doi:10.1111/JCH.14137

25. Pena JE, Rascon-Pacheco RA, Ascencio-Montiel JJ, et al. Hypertension, diabetes and obesity, major risk factors for death in patients with COVID-19 in Mexico. *Arch Med Res*. 2021;52(4):443–449. doi:10.1016/J.ARCMED.2020.12.002

26. Huang S, Wang J, Liu F, et al. COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study. *Hypertens Res*. 2020;43(8):824–831. doi:10.1038/s41440-020-0485-2

27. Ye Z, Zhang Y, Wang Y, Huang Z, Song B. Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review. *Eur Radiol*. 2020;30(8):4381–4389. doi:10.1007/s00330-020-06801-0